FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Barry Potter

Research Profile

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Nicolás Veiga; Himali Y Godage; Kerman Gómez; Gabriel González; Israel Macho; Barry V L Potter; Andrew M Riley; Julia Torres; Carlos Kremer
Inframolecular acid-base and coordination properties towards Na(+) and Mg(2+) of myo-inositol 1,3,4,5,6-pentakisphosphate: a structural approach to biologically relevant species.
L W Lawrence Woo; Paul M Wood; Christian Bubert; Atul Purohit; Mark P Thomas; Barry V L Potter
Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate.
Samir A Khan; Barry V L Potter; Andrew M Riley; Ana M Rossi; Colin W Taylor
Subtype-selective regulation of IP(3) receptors by thimerosal via cysteine residues within the IP(3)-binding core and suppressor domain.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Barry Potter (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nicolás Veiga; Himali Y Godage; Kerman Gómez; Gabriel González; Israel Macho; Barry V L Potter; Andrew M Riley; Julia Torres; Carlos Kremer
Inframolecular acid-base and coordination properties towards Na(+) and Mg(2+) of myo-inositol 1,3,4,5,6-pentakisphosphate: a structural approach to biologically relevant species.
Dalton transactions (Cambridge, England : 2003) 2013;42(17):6021-32.
2013: L W Lawrence Woo; Paul M Wood; Christian Bubert; Atul Purohit; Mark P Thomas; Barry V L Potter
Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate.
ChemMedChem 2013;8(5):779-99.
2013: Samir A Khan; Barry V L Potter; Andrew M Riley; Ana M Rossi; Colin W Taylor
Subtype-selective regulation of IP(3) receptors by thimerosal via cysteine residues within the IP(3)-binding core and suppressor domain.
The Biochemical journal 2013;451(2):177-84.
2013: H Yasmin Godage; Mary F Mahon; Andrew M Riley; Mark P Thomas; Timothy J Woodman; Barry V L Potter
Regioselective opening of myo-inositol orthoesters: mechanism and synthetic utility.
The Journal of organic chemistry 2013;78(6):2275-88.
2013: Huma Saleem; Barry V L Potter; Andrew M Riley; Stephen C Tovey; Colin W Taylor
Stimulation of inositol 1,4,5-trisphosphate (IP3) receptor subtypes by adenophostin A and its analogues.
PloS one 2013;8(2):e58027.
2013: Huma Saleem; Barry V L Potter; Taufiq Rahman; Andrew M Riley; Stephen C Tovey; Colin W Taylor
Stimulation of inositol 1,4,5-trisphosphate (IP3) receptor subtypes by analogues of IP3.
PloS one 2013;8(1):e54877.
2013: Joanna M Day; Paul A Foster; Jonathan D Hargrave; Barry V L Potter; Michael J Reed; Fabien Schmidlin; christopher sharland; Helena Tutill; Nigel Vicker; Atul Purohit
STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Endocrine-related cancer 2013;20(1):53-64.
2012: Andrew M Riley; Stephen B Shears; Huanchen Wang; Jeremy D Weaver; Barry V L Potter
First synthetic analogues of diphosphoinositol polyphosphates: interaction with PP-InsP5 kinase.
Chemical communications (Cambridge, England) 2012;48(92):11292-4.
2012: Xiangdong SU; Mark P Thomas; Nigel Vicker; Michael D Culler; Heather A Halem; Cecile Moutrille; Barry V L Potter
Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Bioorganic & medicinal chemistry 2012;20(21):6394-402.
2012: Stephen Joseph Mills; Pär Nordlund; Camilla Persson; Gyles Cozier; Christophe Erneux; Andrew M Riley; Mark P Thomas; Lionel Trésaugues; Barry V L Potter
A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery.
ACS chemical biology 2012;7(5):822-8.
2012: Joanna M Swarbrick; Barry V L Potter
Total synthesis of a cyclic adenosine 5'-diphosphate ribose receptor agonist.
The Journal of organic chemistry 2012;77(9):4191-7.
2012: Benjamin L Turner; Andrew M Riley; Alexander W Cheesman; H Yasmin Godage; Barry V L Potter
Determination of neo- and D-chiro-inositol hexakisphosphate in soils by solution 31P NMR spectroscopy.
Environmental science & technology 2012;46(9):4994-5002.
2012: L W Lawrence Woo; Bertrand Leblond; Atul Purohit; Barry V L Potter
Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors.
Bioorganic & medicinal chemistry 2012;20(8):2506-19.
2012: Christelle Moreau; Andreas H Guse; Tanja Kirchberger; Mark P Thomas; Karin Weber; Bo Zhang; Barry V L Potter
Aberrant cyclization affords a C-6 modified cyclic adenosine 5'-diphosphoribose analogue with biological activity in Jurkat T cells.
Journal of medicinal chemistry 2012;55(4):1478-89.
2012: Kana M Sureshan; Colin W Taylor; Mark P Thomas; Stephen C Tovey; Andrew M Riley; Barry V L Potter
Contribution of phosphates and adenine to the potency of adenophostins at the IP₃ receptor: synthesis of all possible bisphosphates of adenophostin A.
Journal of medicinal chemistry 2012;55(4):1706-20.
2011: L W Lawrence Woo; Atul Purohit; Oliver B Sutcliffe; Mark P Thomas; Dharshini Ganeshapillai; Mary F Mahon; Bindu Malini; Barry V L Potter
Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495).
ChemMedChem 2011;6(11):2019-34.
2011: Xiangdong SU; Mark P Thomas; Nigel Vicker; Michael D Culler; Heather Halem; Fabienne Pradaux-Caggiano; Barry V L Potter
Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.
ChemMedChem 2011;6(9):1616-29.
2011: Paul M Wood; Mary F Mahon; Atul Purohit; Mark P Thomas; L W Lawrence Woo; Barry V L Potter
Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates.
ChemMedChem 2011;6(8):1423-38.
2011: Xiangdong SU; Mark P Thomas; Nigel Vicker; Michael D Culler; Heather Halem; Fabienne Pradaux-Caggiano; Barry V L Potter
Discovery of adamantyl heterocyclic ketones as potent 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
ChemMedChem 2011;6(8):1439-51.
2011: Fabrice Jourdan; Mathew P Leese; Simon P Newman; Surinder Chander; Wolfgang Dohle; Eric Ferrandis; Atul Purohit; Barry V L Potter
Structure-activity relationships of C-17-substituted estratriene-3-O-sulfamates as anticancer agents.
Journal of medicinal chemistry 2011;54(13):4863-79.
2011: Atul Purohit; L W Lawrence Woo; Barry V L Potter
Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism.
Molecular and cellular endocrinology 2011;340(2):154-60.
2011: L W Lawrence Woo; Atul Purohit; Barry V L Potter
Development of steroid sulfatase inhibitors.
Molecular and cellular endocrinology 2011;340(2):175-85.
2011: Christelle Moreau; Gloria A Ashamu; Victoria C Bailey; Antony Galione; Andreas H Guse; Barry V L Potter
Synthesis of cyclic adenosine 5'-diphosphate ribose analogues: a C2'endo/syn "southern" ribose conformation underlies activity at the sea urchin cADPR receptor.
Organic & biomolecular chemistry 2011;9(1):278-90.
2010: Paul M Wood; L W Lawrence Woo; Jean-Robert Labrosse; Mark P Thomas; Mary F Mahon; Surinder K Chander; Atul Purohit; Michael J Reed; Barry V L Potter
Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-bromo-4-{[(4-cyanophenyl)(4h-1,2,4-triazol-4-yl)amino]methyl}phenylsulfamate: synthesis, SAR, crystal structure, and in vitro and in vivo activities.
ChemMedChem 2010;5(9):1577-93.
2010: Xiangdong SU; Fabienne Pradaux-Caggiano; Mark P Thomas; Michelle W Y Szeto; Heather A Halem; Michael D Culler; Nigel Vicker; Barry V L Potter
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
ChemMedChem 2010;5(7):1026-44.
2010: Chiara Cordiglieri; Francesca Odoardi; Bo Zhang; Merle Nebel; Naoto Kawakami; Wolfgang E F Klinkert; Dimtri Lodygin; Fred Lühder; Esther Breunig; Detlev Schild; Vijay Kumar Ulaganathan; Klaus Dornmair; Werner Dammermann; Barry V L Potter; Andreas H Guse; Alexander Flügel
Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system.
Brain : a journal of neurology 2010;133(Pt 7):1930-43.
2010: Zhao Ding; Ana M Rossi; Andrew M Riley; Taufiq Rahman; Barry V L Potter; Colin W Taylor
Binding of inositol 1,4,5-trisphosphate (IP3) and adenophostin A to the N-terminal region of the IP3 receptor: thermodynamic analysis using fluorescence polarization with a novel IP3 receptor ligand.
Molecular pharmacology 2010;77(6):995-1004.
2010: Mathew P Leese; Fabrice Jourdan; Meriel R Kimberley; Gyles E Cozier; Nethaji Thiyagarajan; Chloe Stengel; Sandra Regis-Lydi; Paul A Foster; Simon P Newman; K Ravi Acharya; Eric Ferrandis; Atul Purohit; Michael J Reed; Barry V L Potter
Chimeric microtubule disruptors.
Chemical communications (Cambridge, England) 2010;46(17):2907-9.
2010: Gyles E Cozier; Mathew P Leese; Matthew D Lloyd; Matthew D Baker; Nethaji Thiyagarajan; K Ravi Acharya; Barry V L Potter
Structures of human carbonic anhydrase II/inhibitor complexes reveal a second binding site for steroidal and nonsteroidal inhibitors.
Biochemistry 2010;49(16):3464-76.
2010: Fabrice Jourdan; Mathew P Leese; Wolfgang Dohle; Ernest Hamel; Eric Ferrandis; Simon P Newman; Atul Purohit; Michael J Reed; Barry V L Potter
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.
Journal of medicinal chemistry 2010;53(7):2942-51.
2010: L W Lawrence Woo; Toby Jackson; Aurélien Putey; Gyles Cozier; Philip Leonard; K Ravi Acharya; Surinder K Chander; Atul Purohit; Michael J Reed; Barry V L Potter
Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template.
Journal of medicinal chemistry 2010;53(5):2155-70.
2010: Ana M Rossi; Barry V L Potter; Andrew M Riley; Colin W Taylor
Adenophostins: High-Affinity Agonists of IP(3) Receptors.
Current topics in membranes 2010;66C():209-33.
2009: Qun Liu; Richard Graeff; Irina A Kriksunov; Hong Jiang; Bo Zhang; Norman Oppenheimer; Hening Lin; Barry V L Potter; Hon Cheung Lee; Quan Hao
Structural basis for enzymatic evolution from a dedicated ADP-ribosyl cyclase to a multifunctional NAD hydrolase.
The Journal of biological chemistry 2009;284(40):27637-45.
2009: Paul A Foster; Yaik T Ho; Simon P Newman; Mathew P Leese; Barry V L Potter; Michael J Reed; Atul Purohit
STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells.
Anticancer research 2009;29(10):3751-7.
2009: Sergio Abbate; Giovanna Longhi; Ettore Castiglioni; France Lebon; Paul M Wood; Lawrence W L Woo; Barry V L Potter
Determination of the absolute configuration of aromatase and dual aromatase-sulfatase inhibitors by vibrational and electronic circular dichroism spectra analysis.
Chirality 2009;21(9):802-8.
2009: Ana M Rossi; Andrew M Riley; Stephen C Tovey; Taufiq Rahman; Olivier DELLIS; Emily J A Taylor; Valery G Veresov; Barry V L Potter; Colin W Taylor
Synthetic partial agonists reveal key steps in IP3 receptor activation.
Nature chemical biology 2009;5(9):631-9.
2009: Nicolás Veiga; Julia Torres; Himali Y Godage; Andrew M Riley; Sixto Domínguez; Barry V L Potter; Alvaro Díaz; Carlos Kremer
The behaviour of inositol 1,3,4,5,6-pentakisphosphate in the presence of the major biological metal cations.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 2009;14(7):1001-13.
2009: Tanja Kirchberger; Christelle Moreau; Gerd K Wagner; Ralf Fliegert; Cornelia C Siebrands; Merle Nebel; Frederike Schmid; Angelika Harneit; Francesca Odoardi; Alexander Flügel; Barry V L Potter; Andreas H Guse
8-Bromo-cyclic inosine diphosphoribose: towards a selective cyclic ADP-ribose agonist.
The Biochemical journal 2009;422(1):139-49.
2009: Werner Dammermann; Bo Zhang; Merle Nebel; Chiara Cordiglieri; Francesca Odoardi; Tanja Kirchberger; Naoto Kawakami; James Dowden; Frederike Schmid; Klaus Dornmair; Martin Hohenegger; Alexander Flügel; Andreas H Guse; Barry V L Potter
NAADP-mediated Ca2+ signaling via type 1 ryanodine receptor in T cells revealed by a synthetic NAADP antagonist.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(26):10678-83.
2009: Joanna M Day; Helena Tutill; Paul A Foster; Helen V Bailey; Wesley B Heaton; christopher sharland; Nigel Vicker; Barry V L Potter; Atul Purohit; Michael J Reed
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Molecular and cellular endocrinology 2009;301(1-2):251-8.
2009: Xiangdong SU; Nigel Vicker; Melanie Trusselle; Heather Halem; Michael D Culler; Barry V L Potter
Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Molecular and cellular endocrinology 2009;301(1-2):169-73.
2009: Nigel Vicker; christopher sharland; Wesley B Heaton; Ana M Ramos Gonzalez; Helen V Bailey; Andrew Smith; Jeremy S Springall; Joanna M Day; Helena Tutill; Michael J Reed; Atul Purohit; Barry V L Potter
The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
Molecular and cellular endocrinology 2009;301(1-2):259-65.
2009: Kana M Sureshan; Andrew M Riley; Ana M Rossi; Stephen C Tovey; Skarlatos G Dedos; Colin W Taylor; Barry V L Potter
Activation of IP(3) receptors by synthetic bisphosphate ligands.
Chemical communications (Cambridge, England) 2009;(10):1204-6.
2009: J M Day; Paul A Foster; Helena Tutill; Simon P Newman; Y T Ho; M P Leese; Barry V L Potter; Michael J Reed; Atul Purohit
BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.
British journal of cancer 2009;100(3):476-86.
2009: Joanna M Day; Atul Purohit; Helena Tutill; Paul A Foster; L W Lawrence Woo; Barry V L Potter; Michael J Reed
The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy.
Annals of the New York Academy of Sciences 2009;1155():80-7.
2008: Fabrice Jourdan; Christian Bubert; Mathew P Leese; Andrew Smith; Eric Ferrandis; Sandra Regis-Lydi; Simon P Newman; Atul Purohit; Michael J Reed; Barry V L Potter
Effects of C-17 heterocyclic substituents on the anticancer activity of 2-ethylestra-1,3,5(10)-triene-3-O-sulfamates: synthesis, in vitro evaluation and computational modelling.
Organic & biomolecular chemistry 2008;6(22):4108-19.
2008: M F C Parsons; Paul A Foster; Surinder K Chander; R Jhalli; Simon P Newman; Mathew P Leese; Barry V L Potter; Atul Purohit; Michael J Reed
The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.
British journal of cancer 2008;99(9):1433-41.
2008: Christian Bubert; L W Lawrence Woo; Oliver B Sutcliffe; Mary F Mahon; Surinder K Chander; Atul Purohit; Michael J Reed; Barry V L Potter
Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile: SAR, crystal structures, in vitro and in vivo activities.
ChemMedChem 2008;3(11):1708-30.
2008: Paul A Foster; Surinder K Chander; Simon P Newman; L W Lawrence Woo; Oliver B Sutcliffe; Christian Bubert; Dujin Zhou; Shiuan Chen; Barry V L Potter; Michael J Reed; Atul Purohit
A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6469-77.
2008: Paul A Foster; Yaik T Ho; Simon P Newman; Philip G Kasprzyk; Mathew P Leese; Barry V L Potter; Michael J Reed; Atul Purohit
2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique.
Breast cancer research and treatment 2008;111(2):251-60.
2008: Paul A Foster; Surinder K Chander; Michael F C Parsons; Simon P Newman; L W Lawrence Woo; Barry V L Potter; Michael J Reed; Atul Purohit
Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.
Breast cancer research and treatment 2008;111(1):129-38.
2008: L W Lawrence Woo; Delphine S Fischer; christopher sharland; Melanie N Trusselle; Paul A Foster; Surinder K Chander; Anna Di Fiore; Claudiu T Supuran; Giuseppina De simone; Atul Purohit; Michael J Reed; Barry V L Potter
Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography.
Molecular cancer therapeutics 2008;7(8):2435-44.
2008: Paul A Foster; L W Lawrence Woo; Barry V L Potter; Michael J Reed; Atul Purohit
The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer.
Endocrinology 2008;149(8):4035-42.
2008: Paul M Wood; L W Lawrence Woo; Jean-Robert Labrosse; Melanie N Trusselle; Sergio Abbate; Giovanna Longhi; Ettore Castiglioni; France Lebon; Atul Purohit; Michael J Reed; Barry V L Potter
Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity.
Journal of medicinal chemistry 2008;51(14):4226-38.
2008: Stephen Joseph Mills; Fabrice Vandeput; Melanie N Trusselle; Steve Safrany; Christophe Erneux; Barry V L Potter
Benzene polyphosphates as tools for cell signalling: inhibition of inositol 1,4,5-trisphosphate 5-phosphatase and interaction with the PH domain of protein kinase Balpha.
Chembiochem : a European journal of chemical biology 2008;9(11):1757-66.
2008: Atul Purohit; Surinder K Chander; L W Lawrence Woo; M F C Parsons; R Jhalli; Barry V L Potter; Michael J Reed
Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy.
Anticancer research 2008;28(3A):1517-23.
2008: Paul A Foster; C Stengel; Tauhid Ali; Mathew P Leese; Barry V L Potter; Michael J Reed; Atul Purohit; Simon P Newman
A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140.
Anticancer research 2008;28(3A):1483-91.
2008: Joanna M Day; Paul A Foster; Helena Tutill; Michael F C Parsons; Simon P Newman; Surinder K Chander; Gillian M Allan; Harshani R Lawrence; Nigel Vicker; Barry V L Potter; Michael J Reed; Atul Purohit
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
International journal of cancer. Journal international du cancer 2008;122(9):1931-40.
2008: Gillian M Allan; Nigel Vicker; Harshani R Lawrence; Helena Tutill; Joanna M Day; Marion Huchet; Eric Ferrandis; Michael J Reed; Atul Purohit; Barry V L Potter
Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
Bioorganic & medicinal chemistry 2008;16(8):4438-56.
2008: Toby Jackson; L W Lawrence Woo; Melanie N Trusselle; Atul Purohit; Michael J Reed; Barry V L Potter
Non-steroidal aromatase inhibitors based on a biphenyl scaffold: synthesis, in vitro SAR, and molecular modelling.
ChemMedChem 2008;3(4):603-18.
2008: Bo Zhang; Gerd K Wagner; Karin Weber; Clive Garnham; Anthony J Morgan; Antony Galione; Andreas H Guse; Barry V L Potter
2'-deoxy cyclic adenosine 5'-diphosphate ribose derivatives: importance of the 2'-hydroxyl motif for the antagonistic activity of 8-substituted cADPR derivatives.
Journal of medicinal chemistry 2008;51(6):1623-36.
2008: Mathew P Leese; Fabrice L Jourdan; Keira Gaukroger; Mary F Mahon; Simon P Newman; Paul A Foster; Chloe Stengel; Sandra Regis-Lydi; Eric Ferrandis; Anna Di Fiore; Giuseppina De simone; Claudiu T Supuran; Atul Purohit; Michael J Reed; Barry V L Potter
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
Journal of medicinal chemistry 2008;51(5):1295-308.
2008: Kana M Sureshan; Melanie N Trusselle; Stephen C Tovey; Colin W Taylor; Barry V L Potter
2-Position base-modified analogues of adenophostin A as high-affinity agonists of the D-myo-inositol trisphosphate receptor: in vitro evaluation and molecular modeling.
The Journal of organic chemistry 2008;73(5):1682-92.
2008: Bo Zhang; VC Bailey; Barry V L Potter
Chemoenzymatic synthesis of 7-deaza cyclic adenosine 5'-diphosphate ribose analogues, membrane-permeant modulators of intracellular calcium release.
The Journal of organic chemistry 2008;73(5):1693-703.
2008: Pavla Bojarová; Emma Denehy; Ian Walker; Karen Loft; David P De Souza; L W Lawrence Woo; Barry V L Potter; Malcolm J McConville; Spencer J Williams
Direct evidence for ArO-S bond cleavage upon inactivation of Pseudomonas aeruginosa arylsulfatase by aryl sulfamates.
Chembiochem : a European journal of chemical biology 2008;9(4):613-23.
2008: Paul A Foster; Simon P Newman; Mathew P Leese; Sonia Bernetiere; Christian Diolez; Jose CAMARA; Beatrice Hacher; Marie-Madeleine Baronnet; Tauhid Ali; Barry V L Potter; Michael J Reed; Atul Purohit
A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer.
Anticancer research 2008;28(2A):577-81.
2008: Simon P Newman; Paul A Foster; Chloe Stengel; Joanna M Day; Yaik T Ho; Jean-Gabriel Judde; Myriam Lassalle; Gregoire Prevost; Mathew P Leese; Barry V L Potter; Michael J Reed; Atul Purohit
STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):597-606.
2008: Xiangdong SU; Nigel Vicker; Barry V L Potter
Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Progress in medicinal chemistry 2008;46():29-130.
2007: Simon P Newman; Paul A Foster; Yaik T Ho; Joanna M Day; Bindumalini Raobaikady; Philip G Kasprzyk; Mathew P Leese; Barry V L Potter; Michael J Reed; Atul Purohit
The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers.
British journal of cancer 2007;97(12):1673-82.
2007: Toby Jackson; L W Lawrence Woo; Melanie N Trusselle; Surinder K Chander; Atul Purohit; Michael J Reed; Barry V L Potter
Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.
Organic & biomolecular chemistry 2007;5(20):2940-52.
2007: Toby Jackson; L W Lawrence Woo; Melanie N Trusselle; Surinder K Chander; Atul Purohit; Michael J Reed; Barry V L Potter
Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.
Organic & biomolecular chemistry 2007;5(18):2940-52.
2007: Christian Bubert; Mathew P Leese; Mary F Mahon; Eric Ferrandis; Sandra Regis-Lydi; Philip G Kasprzyk; Simon P Newman; Yaik T Ho; Atul Purohit; Michael J Reed; Barry V L Potter
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity.
Journal of medicinal chemistry 2007;50(18):4431-43.
2007: Qun Liu; Irina A Kriksunov; Christelle Moreau; Richard Graeff; Barry V L Potter; Hon Cheung Lee; Quan Hao
Catalysis-associated conformational changes revealed by human CD38 complexed with a non-hydrolyzable substrate analog.
The Journal of biological chemistry 2007;282(34):24825-32.
2007: L W Lawrence Woo; Christian Bubert; Oliver B Sutcliffe; Andrew Smith; Surinder K Chander; Mary F Mahon; Atul Purohit; Michael J Reed; Barry V L Potter
Dual aromatase-steroid sulfatase inhibitors.
Journal of medicinal chemistry 2007;50(15):3540-60.
2007: Surinder K Chander; Paul A Foster; Mathew P Leese; Simon P Newman; Barry V L Potter; Atul Purohit; Michael J Reed
In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol.
British journal of cancer 2007;96(9):1368-76.
2007: Xiangdong SU; Nigel Vicker; Harshani R Lawrence; Andrew Smith; Atul Purohit; Michael J Reed; Barry V L Potter
Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives.
The Journal of steroid biochemistry and molecular biology 2007;104(3-5):312-20.
2007: Nigel Vicker; Xiangdong SU; Dharshini Ganeshapillai; Andrew Smith; Atul Purohit; Michael J Reed; Barry V L Potter
Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
The Journal of steroid biochemistry and molecular biology 2007;104(3-5):123-9.
2007: Fabrice Vandeput; Laurent Combettes; Stephen Joseph Mills; Katrien Backers; Alexandre Wohlkönig; Jan B Parys; Humbert De Smedt; Ludwig Missiaen; Geneviève Dupont; Barry V L Potter; Christophe Erneux
Biphenyl 2,3',4,5',6-pentakisphosphate, a novel inositol polyphosphate surrogate, modulates Ca2+ responses in rat hepatocytes.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007;21(7):1481-91.
2007: Stephen Joseph Mills; David Komander; Melanie N Trusselle; Steve Safrany; Daan M F van Aalten; Barry V L Potter
Novel inositol phospholipid headgroup surrogate crystallized in the pleckstrin homology domain of protein kinase Balpha.
ACS chemical biology 2007;2(4):242-6.
2007: Bo Zhang; Hélène Muller-Steffner; Francis Schuber; Barry V L Potter
Nicotinamide 2-fluoroadenine dinucleotide unmasks the NAD+ glycohydrolase activity of Aplysia californica adenosine 5'-diphosphate ribosyl cyclase.
Biochemistry 2007;46(13):4100-9.
2007: Susannah J Stanway; Patrick Delavault; Atul Purohit; L W Lawrence Woo; Christophe Thurieau; Barry V L Potter; Michael J Reed
Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
The oncologist 2007;12(4):370-4.
2006: Mathew P Leese; Bertrand Leblond; Andrew Smith; Simon P Newman; Anna Di Fiore; Giuseppina De simone; Claudiu T Supuran; Atul Purohit; Michael J Reed; Barry V L Potter
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity.
Journal of medicinal chemistry 2006;49(26):7683-96.
2006: Stephen Joseph Mills; Hélène Dozol; Fabrice Vandeput; Katrien Backers; Timothy Woodman; Christophe Erneux; Bernard Spiess; Barry V L Potter
3-hydroxybenzene 1,2,4-trisphosphate, a novel second messenger mimic and unusual substrate for type-I myo-inositol 1,4,5-trisphosphate 5-phosphatase: Synthesis and physicochemistry.
Chembiochem : a European journal of chemical biology 2006;7(11):1696-706.
2006: T Kirchberger; G Wagner; J Xu; C Cordiglieri; P Wang; Andreas Gasser; Ralf Fliegert; S Bruhn; Alexander Flügel; Frances E Lund; L-H Zhang; Barry V L Potter; Andreas H Guse
Cellular effects and metabolic stability of N1-cyclic inosine diphosphoribose and its derivatives.
British journal of pharmacology 2006;149(4):337-44.
2006: Tetsuya Mochizuki; Yoshihiko Kondo; Hiroshi Abe; Stephen C Tovey; Skarlatos G Dedos; Colin W Taylor; Michael Paul; Barry V L Potter; Akira Matsuda; Satoshi Shuto
Synthesis of adenophostin A analogues conjugating an aromatic group at the 5'-position as potent IP3 receptor ligands.
Journal of medicinal chemistry 2006;49(19):5750-8.
2006: Paul A Foster; Simon P Newman; Surinder K Chander; Chloe Stengel; Roma Jhalli; Lawrence L W Woo; Barry V L Potter; Michael J Reed; Atul Purohit
In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(18):5543-9.
2006: Christelle Moreau; Gerd K Wagner; Karin Weber; Andreas H Guse; Barry V L Potter
Structural determinants for N1/N7 cyclization of nicotinamide hypoxanthine 5'-dinucleotide (NHD+) derivatives by ADP-ribosyl cyclase from aplysia californica: Ca2+-mobilizing activity of 8-substituted cyclic inosine 5'-diphosphoribose analogues in T-lymphocytes.
Journal of medicinal chemistry 2006;49(17):5162-76.
2006: H Yasmin Godage; Andrew M Riley; Timothy J Woodman; Barry V L Potter
Regioselective hydrolysis of myo-inositol 1,3,5-orthobenzoate via a 1,2-bridged 2'-phenyl-1',3'-dioxolan-2'-ylium ion provides a rapid route to the anticancer agent Ins(1,3,4,5,6)P5.
Chemical communications (Cambridge, England) 2006;(28):2989-91.
2006: Andrew M Riley; Melanie N Trusselle; Paul Kuad; Michal Borkovec; Jaiesoon Cho; Jae H Choi; Xun Qian; Stephen B Shears; Bernard Spiess; Barry V L Potter
scyllo-inositol pentakisphosphate as an analogue of myo-inositol 1,3,4,5,6-pentakisphosphate: chemical synthesis, physicochemistry and biological applications.
Chembiochem : a European journal of chemical biology 2006;7(7):1114-22.
2006: James Dowden; Georgina Berridge; Christelle Moreau; Michiko Yamasaki; Grant C Churchill; Barry V L Potter; Antony Galione
Cell-permeant small-molecule modulators of NAADP-mediated Ca2+ release.
Chemistry & biology 2006;13(6):659-65.
2006: Kana M Sureshan; Melanie N Trusselle; Stephen C Tovey; Colin W Taylor; Barry V L Potter
Guanophostin A: Synthesis and evaluation of a high affinity agonist of the D-myo-inositol 1,4,5-trisphosphate receptor.
Chemical communications (Cambridge, England) 2006;(19):2015-7.
2006: Nigel Vicker; Harshani R Lawrence; Gillian M Allan; Christian Bubert; Andrew Smith; Helena Tutill; Atul Purohit; Joanna M Day; Mary F Mahon; Michael J Reed; Barry V L Potter
Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
ChemMedChem 2006;1(4):464-81.
2006: Tetsuya Mochizuki; Yoshihiko Kondo; Hiroshi Abe; Colin W Taylor; Barry V L Potter; Akira Matsuda; Satoshi Shuto
Design and synthesis of 5'-deoxy-5'-phenyladenophostin A, a highly potent IP3 receptor ligand.
Organic letters 2006;8(7):1455-8.
2006: Joanna M Day; Helena Tutill; Simon P Newman; Atul Purohit; Harshani R Lawrence; Nigel Vicker; Barry V L Potter; Michael J Reed
17Beta-hydroxysteroid dehydrogenase Type 1 and Type 2: association between mRNA expression and activity in cell lines.
Molecular and cellular endocrinology 2006;248(1-2):246-9.
2006: Atul Purohit; Helena Tutill; Joanna M Day; Surinder K Chander; Harshani R Lawrence; Gillian M Allan; Delphine S Fischer; Nigel Vicker; Simon P Newman; Barry V L Potter; Michael J Reed
The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Molecular and cellular endocrinology 2006;248(1-2):199-203.
2006: Gillian M Allan; Christian Bubert; Nigel Vicker; Andrew Smith; Helena Tutill; Atul Purohit; Michael J Reed; Barry V L Potter
Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Molecular and cellular endocrinology 2006;248(1-2):204-7.
2006: Xiangdong SU; Nigel Vicker; Dharshini Ganeshapillai; Andrew Smith; Atul Purohit; Michael J Reed; Barry V L Potter
Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Molecular and cellular endocrinology 2006;248(1-2):214-7.
2006: Masaru Terauchi; Hiroshi Abe; Stephen C Tovey; Skarlatos G Dedos; Colin W Taylor; Michael Paul; Melanie N Trusselle; Barry V L Potter; Akira Matsuda; Satoshi Shuto
A systematic study of C-glucoside trisphosphates as myo-inositol trisphosphate receptor ligands. Synthesis of beta-C-glucoside trisphosphates based on the conformational restriction strategy.
Journal of medicinal chemistry 2006;49(6):1900-9.
2006: Christelle Moreau; Timothy J Woodman; Barry V L Potter
Unusual entry to the novel 8-halo-N1-ribosyl hypoxanthine system by degradation of a cyclic adenosine-5'-diphosphate ribose analogue.
Chemical communications (Cambridge, England) 2006;(10):1127-9.
2006: Susannah J Stanway; Atul Purohit; L W Lawrence Woo; Saulat Sufi; David M Vigushin; Rebecca Ward; Richard H Wilson; Frank Z Stanczyk; Nicola Dobbs; Elena Kulinskaya; Moira Elliott; Barry V L Potter; Michael J Reed; R Charles Coombes
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(5):1585-92.
2006: Gillian M Allan; Harshani R Lawrence; Josephine Cornet; Christian Bubert; Delphine S Fischer; Nigel Vicker; Andrew Smith; Helena Tutill; Atul Purohit; Joanna M Day; Mary F Mahon; Michael J Reed; Barry V L Potter
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Journal of medicinal chemistry 2006;49(4):1325-45.
2006: Andrew M Riley; Sandrine Deleu; Xun Qian; Jennifer Mitchell; Sung-Kee Chung; Stephan Adelt; Günter Vogel; Barry V L Potter; Stephen B Shears
On the contribution of stereochemistry to human ITPK1 specificity: Ins(1,4,5,6)P4 is not a physiologic substrate.
FEBS letters 2006;580(1):324-30.
2006: Simon P Newman; Christopher R Ireson; Helena Tutill; Joanna M Day; Michael F C Parsons; Mathew P Leese; Barry V L Potter; Michael J Reed; Atul Purohit
The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells.
Cancer research 2006;66(1):324-30.
2005: Bindumalini Raobaikady; Michael J Reed; Mathew P Leese; Barry V L Potter; Atul Purohit
Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates.
International journal of cancer. Journal international du cancer 2005;117(1):150-9.
2005: Tania Maffucci; Enza Piccolo; Albana Cumashi; Manuela Iezzi; Andrew M Riley; Adolfo Saiardi; H Yasmin Godage; Cosmo Rossi; Massimo Broggini; Stefano Iacobelli; Barry V L Potter; Paolo Innocenti; Marco Falasca
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
Cancer research 2005;65(18):8339-49.
2005: Delphine S Fischer; Gillian M Allan; Christian Bubert; Nigel Vicker; Andrew Smith; Helena Tutill; Atul Purohit; Lynn Wood; Graham Packham; Mary F Mahon; Michael J Reed; Barry V L Potter
E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Journal of medicinal chemistry 2005;48(18):5749-70.
2005: Mathew P Leese; Hatem A M Hejaz; Mary F Mahon; Simon P Newman; Atul Purohit; Michael J Reed; Barry V L Potter
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.
Journal of medicinal chemistry 2005;48(16):5243-56.
2005: Alexandra Poinas; Katrien Backers; Andrew M Riley; Stephen Joseph Mills; Colette Moreau; Barry V L Potter; Christophe Erneux
Interaction of the catalytic domain of inositol 1,4,5-trisphosphate 3-kinase A with inositol phosphate analogues.
Chembiochem : a European journal of chemical biology 2005;6(8):1449-57.
2005: Alex J Laude; Stephen C Tovey; Skarlatos G Dedos; Barry V L Potter; Sarah C R Lummis; Colin W Taylor
Rapid functional assays of recombinant IP3 receptors.
Cell calcium 2005;38(1):45-51.
2005: Takashi Kudoh; Masayoshi Fukuoka; Satoshi Ichikawa; Takashi Murayama; Yasuo Ogawa; Minako Hashii; Haruhiro Higashida; Svenja Kunerth; Karin Weber; Andreas H Guse; Barry V L Potter; Akira Matsuda; Satoshi Shuto
Synthesis of stable and cell-type selective analogues of cyclic ADP-ribose, a Ca(2+)-mobilizing second messenger. Structure--activity relationship of the N1-ribose moiety.
Journal of the American Chemical Society 2005;127(24):8846-55.
2005: Gerd K Wagner; Andreas H Guse; Barry V L Potter
Rapid synthetic route toward structurally modified derivatives of cyclic adenosine 5'-diphosphate ribose.
The Journal of organic chemistry 2005;70(12):4810-9.
2005: Matthew D Lloyd; Nethaji Thiyagarajan; Yaik T Ho; L W Lawrence Woo; Oliver B Sutcliffe; Atul Purohit; Michael J Reed; K Ravi Acharya; Barry V L Potter
First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors.
Biochemistry 2005;44(18):6858-66.
2005: Harshani R Lawrence; Nigel Vicker; Gillian M Allan; Andrew Smith; Mary F Mahon; Helena Tutill; Atul Purohit; Michael J Reed; Barry V L Potter
Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Journal of medicinal chemistry 2005;48(8):2759-62.
2005: Michael J Reed; Atul Purohit; L W Lawrence Woo; Simon P Newman; Barry V L Potter
Steroid sulfatase: molecular biology, regulation, and inhibition.
Endocrine reviews 2005;26(2):171-202.
2005: Mathew P Leese; Bertrand Leblond; Simon P Newman; Atul Purohit; Michael J Reed; Barry V L Potter
Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates.
The Journal of steroid biochemistry and molecular biology 2005;94(1-3):239-51.
2005: Bindumalini Raobaikady; Joanna M Day; Atul Purohit; Barry V L Potter; Michael J Reed
The nature of inhibition of steroid sulphatase activity by tibolone and its metabolites.
The Journal of steroid biochemistry and molecular biology 2005;94(1-3):229-37.
2005: T Utsumi; Mathew P Leese; Surinder K Chander; K Gaukroger; Atul Purohit; Simon P Newman; Barry V L Potter; Michael J Reed
The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells.
The Journal of steroid biochemistry and molecular biology 2005;94(1-3):219-27.
2005: Atul Purohit; Margaret W Ghilchik; Mathew P Leese; Barry V L Potter; Michael J Reed
Regulation of aromatase activity by cytokines, PGE2 and 2-methoxyoestrone-3-O-sulphamate in fibroblasts derived from normal and malignant breast tissues.
The Journal of steroid biochemistry and molecular biology 2005;94(1-3):167-72.
2005: Paul M Wood; L W Lawrence Woo; Anna Humphreys; Surinder K Chander; Atul Purohit; Michael J Reed; Barry V L Potter
A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity.
The Journal of steroid biochemistry and molecular biology 2005;94(1-3):123-30.
2005: Matthew D Lloyd; Richard L Pederick; Ramanathan Natesh; L W Lawrence Woo; Atul Purohit; Michael J Reed; K Ravi Acharya; Barry V L Potter
Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent.
The Biochemical journal 2005;385(Pt 3):715-20.
2005: Charles N Borissow; Steven J Black; Michael Paul; Stephen C Tovey; Skarlatos G Dedos; Colin W Taylor; Barry V L Potter
Adenophostin A and analogues modified at the adenine moiety: synthesis, conformational analysis and biological activity.
Organic & biomolecular chemistry 2005;3(2):245-52.
2005: James Dowden; Richard S Brown; Christelle Moreau; Antony Galione; Barry V L Potter
Chemical synthesis of the novel Ca2+ messenger NAADP.
Nucleosides, nucleotides & nucleic acids 2005;24(5-7):513-8.
2004: Lev Solyakov; Kelvin Cain; Beryl M Tracey; Rebekah Jukes; Andrew M Riley; Barry V L Potter; Andrew B Tobin
Regulation of casein kinase-2 (CK2) activity by inositol phosphates.
The Journal of biological chemistry 2004;279(42):43403-10.
2004: Christopher R Ireson; Surinder K Chander; Atul Purohit; David C Parish; L W Lawrence Woo; Barry V L Potter; Michael J Reed
Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats.
British journal of cancer 2004;91(7):1399-404.
2004: Surinder K Chander; Atul Purohit; L W Lawrence Woo; Barry V L Potter; Michael J Reed
The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates.
Biochemical and biophysical research communications 2004;322(1):217-22.
2004: James Dowden; Christelle Moreau; Richard S Brown; Georgina Berridge; Antony Galione; Barry V L Potter
Chemical synthesis of the second messenger nicotinic acid adenine dinucleotide phosphate by total synthesis of nicotinamide adenine dinucleotide phosphate.
Angewandte Chemie (International ed. in English) 2004;43(35):4637-40.
2004: Xiangdong SU; Harshani R Lawrence; Dharshini Ganeshapillai; Adrian Cruttenden; Atul Purohit; Michael J Reed; Nigel Vicker; Barry V L Potter
Novel 18beta-glycyrrhetinic acid analogues as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenases.
Bioorganic & medicinal chemistry 2004;12(16):4439-57.
2004: Graeme Horne; Clarisse Maechling; Andrea Fleig; Masato Hirata; Reinhold Penner; Bernard Spiess; Barry V L Potter
D-6-Deoxy-myo-inositol 1,3,4,5-tetrakisphosphate, a mimic of d-myo-inositol 1,3,4,5-tetrakisphosphate: biological activity and pH-dependent conformational properties.
Biochemical and biophysical research communications 2004;320(4):1262-70.
2004: Roland B Gregory; Rachael Hughes; Andrew M Riley; Barry V L Potter; Robert A Wilcox; Greg J Barritt
Inositol trisphosphate analogues selective for types I and II inositol trisphosphate receptors exert differential effects on vasopressin-stimulated Ca2+ inflow and Ca2+ release from intracellular stores in rat hepatocytes.
The Biochemical journal 2004;381(Pt 2):519-26.
2004: Nigel Vicker; Xiangdong SU; Harshani R Lawrence; Adrian Cruttenden; Atul Purohit; Michael J Reed; Barry V L Potter
A novel 18 beta-glycyrrhetinic acid analogue as a potent and selective inhibitor of 11 beta-hydroxysteroid dehydrogenase 2.
Bioorganic & medicinal chemistry letters 2004;14(12):3263-7.
2004: Mathew P Leese; Simon P Newman; Atul Purohit; Michael J Reed; Barry V L Potter
2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents.
Bioorganic & medicinal chemistry letters 2004;14(12):3135-8.
2004: Andrew M Riley; Hélène Dozol; Bernard Spiess; Barry V L Potter
2-O-(2-Aminoethyl)-myo-inositol 1,4,5-trisphosphate as a novel ligand for conjugation: physicochemical properties and synthesis of a new Ins(1,4,5)P(3) affinity matrix.
Biochemical and biophysical research communications 2004;318(2):444-52.
2004: Hatem A M Hejaz; L W Lawrence Woo; Atul Purohit; Michael J Reed; Barry V L Potter
Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulfatase.
Bioorganic & medicinal chemistry 2004;12(10):2759-72.
2004: L Wood; M P Leese; Amalia Mouzakiti; A Purohit; Barry V L Potter; M J Reed; Graham Packham
2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases.
Apoptosis : an international journal on programmed cell death 2004;9(3):323-32.
2004: Barry V L Potter; Timothy F Walseth
Medicinal chemistry and pharmacology of cyclic ADP-ribose.
Current molecular medicine 2004;4(3):303-11.
2004: Julie E Reed; L W Lawrence Woo; James J Robinson; Bertrand Leblond; Mathew P Leese; Atul Purohit; Michael J Reed; Barry V L Potter
2-difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor.
Biochemical and biophysical research communications 2004;317(1):169-75.
2004: Simon P Newman; Mathew P Leese; Atul Purohit; David R C James; Catherine E Rennie; Barry V L Potter; Michael J Reed
Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates.
International journal of cancer. Journal international du cancer 2004;109(4):533-40.
2004: Svenja Kunerth; Matthias F Langhorst; Nadine Schwarzmann; Xianfeng Gu; Lijun Huang; Zhenjun Yang; Liangren Zhang; Stephen Joseph Mills; Li-He Zhang; Barry V L Potter; Andreas H Guse
Amplification and propagation of pacemaker Ca2+ signals by cyclic ADP-ribose and the type 3 ryanodine receptor in T cells.
Journal of cell science 2004;117(Pt 10):2141-9.
2004: Enza Piccolo; Sara Vignati; Tania Maffucci; Pasquale F Innominato; Andrew M Riley; Barry V L Potter; Pier Paolo Pandolfi; Massimo Broggini; Stefano Iacobelli; Paolo Innocenti; Marco Falasca
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.
Oncogene 2004;23(9):1754-65.
2004: Andrew M Riley; Alex J Laude; Colin W Taylor; Barry V L Potter
Dimers of D-myo-inositol 1,4,5-trisphosphate: design, synthesis, and interaction with Ins(1,4,5)P3 receptors.
Bioconjugate chemistry 2004;15(2):278-89.
2004: Christopher R Ireson; Surinder K Chander; Atul Purohit; S Perera; Simon P Newman; David C Parish; Mathew P Leese; A C Smith; Barry V L Potter; Michael J Reed
Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents.
British journal of cancer 2004;90(4):932-7.
2004: Christopher J W Mort; Marie E Migaud; Antony Galione; Barry V L Potter
Aplysia californica mediated cyclisation of novel 3'-modified NAD+ analogues: a role for hydrogen bonding in the recognition of cyclic adenosine 5'-diphosphate ribose.
Bioorganic & medicinal chemistry 2004;12(2):475-87.
2004: Francesco Abbate; Jean-Yves Winum; Barry V L Potter; Angela Casini; Jean-Louis Montero; Andrea Scozzafava; Claudiu T Supuran
Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase.
Bioorganic & medicinal chemistry letters 2004;14(1):231-4.
2004: Graeme Horne; Stephen Joseph Mills; Barry V L Potter
First derivatives of myo-inositol 1,4,6-trisphosphate modified at positions 2 and 3: structural analogues of D-myo-inositol 1,4,5-trisphosphate.
Carbohydrate research 2004;339(1):51-65.
2003: Stephen Joseph Mills; Andrew M Riley; Changsheng Liu; Mary F Mahon; Barry V L Potter
A definitive synthesis of D-myo-inositol 1,4,5,6-tetrakisphosphate and its enantiomer D-myo-inositol 3,4,5,6-tetrakisphosphate from a novel butane-2,3-diacetal-protected inositol.
Chemistry (Weinheim an der Bergstrasse, Germany) 2003;9(24):6207-14.
2003: Heidi J Rosenberg; Andrew M Riley; Alex J Laude; Colin W Taylor; Barry V L Potter
Synthesis and Ca2+-mobilizing activity of purine-modified mimics of adenophostin A: a model for the adenophostin-Ins(1,4,5)P3 receptor interaction.
Journal of medicinal chemistry 2003;46(23):4860-71.
2003: Satoshi Shuto; Masayoshi Fukuoka; Takashi Kudoh; Clive Garnham; Antony Galione; Barry V L Potter; Akira Matsuda
Convergent synthesis and unexpected Ca(2+)-mobilizing activity of 8-substituted analogues of cyclic ADP-carbocyclic-ribose, a stable mimic of the Ca(2+)-mobilizing second messenger cyclic ADP-ribose.
Journal of medicinal chemistry 2003;46(22):4741-9.
2003: Stephen Joseph Mills; Katrien Backers; Christophe Erneux; Barry V L Potter
Synthesis of D- and L-myo-inositol 1,2,4,6-tetrakisphosphate, regioisomers of myo-inositol 1,3,4,5 tetrakisphosphate: activity against Ins(1,4,5)P3 binding proteins.
Organic & biomolecular chemistry 2003;1(20):3546-56.
2003: Paul Whitley; Barbara J Reaves; Makoto Hashimoto; Andrew M Riley; Barry V L Potter; Geoffrey D Holman
Identification of mammalian Vps24p as an effector of phosphatidylinositol 3,5-bisphosphate-dependent endosome compartmentalization.
The Journal of biological chemistry 2003;278(40):38786-95.
2003: Stephen Joseph Mills; Barry V L Potter
Synthesis of potent Ins(1,4,5)P3 5-phosphatase inhibitors by modification of myo-inositol 1,3,4,6-tetrakisphosphate.
Bioorganic & medicinal chemistry 2003;11(19):4245-53.
2003: Atul Purohit; L W Lawrence Woo; Surinder K Chander; Simon P Newman; Christopher R Ireson; Y Ho; A Grasso; Mathew P Leese; Barry V L Potter; Michael J Reed
Steroid sulphatase inhibitors for breast cancer therapy.
The Journal of steroid biochemistry and molecular biology 2003;86(3-5):423-32.
2003: Gerd K Wagner; Steven Black; Andreas H Guse; Barry V L Potter
First enzymatic synthesis of an N1-cyclised cADPR (cyclic-ADP ribose) analogue with a hypoxanthine partial structure: discovery of a membrane permeant cADPR agonist.
Chemical communications (Cambridge, England) 2003;(15):1944-5.
2003: Yaik T Ho; Simon P Newman; Atul Purohit; Mathew P Leese; Barry V L Potter; Michael J Reed
The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-alpha on endothelial and fibroblast cell growth, morphology and apoptosis.
The Journal of steroid biochemistry and molecular biology 2003;86(2):189-96.
2003: L W Lawrence Woo; Oliver B Sutcliffe; Christian Bubert; Anna Grasso; Surinder K Chander; Atul Purohit; Michael J Reed; Barry V L Potter
First dual aromatase-steroid sulfatase inhibitors.
Journal of medicinal chemistry 2003;46(15):3193-6.
2003: Yaik T Ho; Atul Purohit; Nigel Vicker; Simon P Newman; James J Robinson; Mathew P Leese; Dharshini Ganeshapillai; L W Lawrence Woo; Barry V L Potter; Michael J Reed
Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates.
Biochemical and biophysical research communications 2003;305(4):909-14.
2003: Delphine S Fischer; L W Lawrence Woo; Mary F Mahon; Atul Purohit; Michael J Reed; Barry V L Potter
D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase.
Bioorganic & medicinal chemistry 2003;11(8):1685-700.
2003: Nigel Vicker; Yaikat Ho; James Robinson; Lawrence L W Woo; Atul Purohit; Michael J Reed; Barry V L Potter
Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II.
Bioorganic & medicinal chemistry letters 2003;13(5):863-5.
2003: Bindumalini Raobaikady; Atul Purohit; Surinder K Chander; L W Lawrence Woo; Mathew P Leese; Barry V L Potter; Michael J Reed
Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate.
The Journal of steroid biochemistry and molecular biology 2003;84(2-3):351-8.
2003: Delphine S Fischer; Surinder K Chander; L W Lawrence Woo; Janine C Fenton; Atul Purohit; Michael J Reed; Barry V L Potter
Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity.
The Journal of steroid biochemistry and molecular biology 2003;84(2-3):343-9.
2003: Christopher R Ireson; David C Parish; Atul Purohit; L W Lawrence Woo; Barry V L Potter; Surinder K Chander; Michael J Reed
Development of a sensitive high-performance liquid chromatography method for the detection of 667 COUMATE in vivo.
The Journal of steroid biochemistry and molecular biology 2003;84(2-3):337-42.
2003: Joanna M Day; Simon P Newman; Alexander Comninos; Claire Solomon; Atul Purohit; Mathew P Leese; Barry V L Potter; Michael J Reed
The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells.
The Journal of steroid biochemistry and molecular biology 2003;84(2-3):317-25.
2003: R N Suzuki; Simon P Newman; Atul Purohit; Mathew P Leese; Barry V L Potter; Michael J Reed
Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate.
The Journal of steroid biochemistry and molecular biology 2003;84(2-3):269-78.
2003: Gerd K Wagner; Andrew M Riley; Heidi J Rosenberg; Colin W Taylor; Andreas H Guse; Barry V L Potter
Analogues of cyclic adenosine 5'-diphosphate ribose and adenophostin A, nucleotides in cellular signal transduction.
Nucleic acids research. Supplement (2001) 2003;(3):1-2.
2002: Nicola M Howarth; Atul Purohit; James J Robinson; Nigel Vicker; Michael J Reed; Barry V L Potter
Estrone 3-sulfate mimics, inhibitors of estrone sulfatase activity: homology model construction and docking studies.
Biochemistry 2002;41(50):14801-14.
2002: Stephen Joseph Mills; Changsheng Liu; Barry V L Potter
Synthesis of D- and L-myo-inositol 2,4,5-trisphosphate and trisphosphorothioate: structural analogues of D-myo-inositol 1,4,5-trisphosphate.
Carbohydrate research 2002;337(20):1795-801.
2002: Andrew M Riley; Stephen A Morris; Edmund P Nerou; Vanessa Correa; Barry V L Potter; Colin W Taylor
Interactions of inositol 1,4,5-trisphosphate (IP(3)) receptors with synthetic poly(ethylene glycol)-linked dimers of IP(3) suggest close spacing of the IP(3)-binding sites.
The Journal of biological chemistry 2002;277(43):40290-5.
2002: Stephen A Morris; Edmund P Nerou; Andrew M Riley; Barry V L Potter; Colin W Taylor
Determinants of adenophostin A binding to inositol trisphosphate receptors.
The Biochemical journal 2002;367(Pt 1):113-20.
2002: Andrew M Riley; David J Jenkins; Rachel D Marwood; Barry V L Potter
Synthesis of glucopyranoside-based ligands for D-myo-inositol 1,4,5-trisphosphate receptors.
Carbohydrate research 2002;337(12):1067-82.
2002: Andreas H Guse; Céline Cakir-Kiefer; Masayoshi Fukuoka; Satoshi Shuto; Karin Weber; Victoria C Bailey; Akira Matsuda; Georg W Mayr; Norman Oppenheimer; Francis Schuber; Barry V L Potter
Novel hydrolysis-resistant analogues of cyclic ADP-ribose: modification of the "northern" ribose and calcium release activity.
Biochemistry 2002;41(21):6744-51.
2002: Melisa W Y Ho; Xiaonian Yang; Mark Carew; Tong Zhang; Len Hua; Yong-Uk Kwon; Sung-Kee Chung; Stephan Adelt; Günter Vogel; Andrew M Riley; Barry V L Potter; Stephen B Shears
Regulation of Ins(3,4,5,6)P(4) signaling by a reversible kinase/phosphatase.
Current biology : CB 2002;12(6):477-82.
2002: Anant B Parekh; Andrew M Riley; Barry V L Potter
Adenophostin A and ribophostin, but not inositol 1,4,5-trisphosphate or manno-adenophostin, activate the Ca2+ release-activated Ca2+ current, I(CRAC), in weak intracellular Ca2+ buffer.
The Biochemical journal 2002;361(Pt 1):133-41.
2001: H Schöttelndreier; Barry V L Potter; Georg W Mayr; Andreas H Guse
Mechanisms involved in alpha6beta1-integrin-mediated Ca(2+) signalling.
Cellular signalling 2001;13(12):895-9.
2001: S Shuto; Graeme Horne; Rachel D Marwood; Barry V L Potter
Total synthesis of nucleobase-modified adenophostin A mimics.
Chemistry (Weinheim an der Bergstrasse, Germany) 2001;7(22):4937-46.
2001: Changsheng Liu; Andrew M Riley; X Yang; Stephen B Shears; Barry V L Potter
Synthesis and biological activity of D- and L-chiro-inositol 2,3,4,5-tetrakisphosphate: design of a novel and potent inhibitor of Ins(3,4,5,6)P4 1-kinase/Ins(1,3,4)P3 5/6-kinase.
Journal of medicinal chemistry 2001;44(18):2984-9.
2001: Andrew M Riley; Vanessa Correa; Mary F Mahon; Colin W Taylor; Barry V L Potter
Bicyclic analogues of D-myo-inositol 1,4,5-trisphosphate related to adenophostin A: synthesis and biological activity.
Journal of medicinal chemistry 2001;44(13):2108-17.
2001: Vanessa Correa; Andrew M Riley; S Shuto; Graeme Horne; Edmund P Nerou; Rachel D Marwood; Barry V L Potter; Colin W Taylor
Structural determinants of adenophostin A activity at inositol trisphosphate receptors.
Molecular pharmacology 2001;59(5):1206-15.
2001: Edmund P Nerou; Andrew M Riley; Barry V L Potter; Colin W Taylor
Selective recognition of inositol phosphates by subtypes of the inositol trisphosphate receptor.
The Biochemical journal 2001;355(Pt 1):59-69.
2001: Atul Purohit; L W Lawrence Woo; D Barrow; Hatem A M Hejaz; R I Nicholson; Barry V L Potter; Michael J Reed
Non-steroidal and steroidal sulfamates: new drugs for cancer therapy.
Molecular and cellular endocrinology 2001;171(1-2):129-35.
2001: Graeme Horne; Barry V L Potter
Synthesis of the enantiomers of 6-deoxy-myo-inositol 1,3,4,5-tetrakisphosphate, structural analogues of myo-inositol 1,3,4,5-tetrakisphosphate.
Chemistry (Weinheim an der Bergstrasse, Germany) 2001;7(1):80-7.
2000: Simon P Newman; Atul Purohit; Margaret W Ghilchik; Barry V L Potter; Michael J Reed
Regulation of steroid sulphatase expression and activity in breast cancer.
The Journal of steroid biochemistry and molecular biology 2000;75(4-5):259-64.
2000: B Malini; Atul Purohit; Dharshini Ganeshapillai; L W Lawrence Woo; Barry V L Potter; Michael J Reed
Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates.
The Journal of steroid biochemistry and molecular biology 2000;75(4-5):253-8.
2000: CE Adkins; Frank Wissing; Barry V L Potter; Colin W Taylor
Rapid activation and partial inactivation of inositol trisphosphate receptors by adenophostin A.
The Biochemical journal 2000;352 Pt 3():929-33.
2000: J Bonser; J Walker; Atul Purohit; Michael J Reed; Barry V L Potter; DS Willis; Stephen Franks; Helen D Mason
Human granulosa cells are a site of sulphatase activity and are able to utilize dehydroepiandrosterone sulphate as a precursor for oestradiol production.
The Journal of endocrinology 2000;167(3):465-71.
2000: Rachel D Marwood; David J Jenkins; Vanessa Correa; Colin W Taylor; Barry V L Potter
Contribution of the adenine base to the activity of adenophostin A investigated using a base replacement strategy.
Journal of medicinal chemistry 2000;43(22):4278-87.
2000: Heidi J Rosenberg; Andrew M Riley; Vanessa Correa; Colin W Taylor; Barry V L Potter
C-glycoside based mimics of D-myo-inositol 1,4,5-trisphosphate.
Carbohydrate research 2000;329(1):7-16.
2000: Lawrence L W Woo; Atul Purohit; B Malini; Michael J Reed; Barry V L Potter
Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates.
Chemistry & biology 2000;7(10):773-91.
2000: I Berg; Barry V L Potter; Georg W Mayr; Andreas H Guse
Nicotinic acid adenine dinucleotide phosphate (NAADP(+)) is an essential regulator of T-lymphocyte Ca(2+)-signaling.
The Journal of cell biology 2000;150(3):581-8.
2000: Atul Purohit; L W Lawrence Woo; Barry V L Potter; Michael J Reed
In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE.
Cancer research 2000;60(13):3394-6.
2000: CT Murphy; Andrew M Riley; Stephen Joseph Mills; C J Lindley; Barry V L Potter; John Westwick
myo-inositol 1,4,6-trisphosphorothioate and myo-inositol 1,3, 6-trisphosphorothioate: partial agonists with very low intrinsic activity at the platelet myo-inositol 1,4,5-trisphosphate receptor.
Molecular pharmacology 2000;57(3):595-601.
2000: A Singh; Atul Purohit; Hatem A M Hejaz; Barry V L Potter; Michael J Reed
Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate.
Molecular and cellular endocrinology 2000;160(1-2):61-6.
2000: Atul Purohit; Hatem A M Hejaz; L Walden; L MacCarthy-Morrogh; Graham Packham; Barry V L Potter; Michael J Reed
The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours.
International journal of cancer. Journal international du cancer 2000;85(4):584-9.
1999: Marc Felemez; R D Marwood; Barry V L Potter; Bernard Spiess
Inframolecular studies of the protonation of adenophostin A: comparison with 1-D-myo-inositol 1,4,5-trisphosphate.
Biochemical and biophysical research communications 1999;266(2):334-40.
1999: Martin Hohenegger; I Berg; Lukas Weigl; Georg W Mayr; Barry V L Potter; Andreas H Guse
Pharmacological activation of the ryanodine receptor in Jurkat T-lymphocytes.
British journal of pharmacology 1999;128(6):1235-40.
1999: M Reyes-Harde; Barry V L Potter; Antony Galione; Patric Stanton
Induction of hippocampal LTD requires nitric-oxide-stimulated PKG activity and Ca2+ release from cyclic ADP-ribose-sensitive stores.
Journal of neurophysiology 1999;82(3):1569-76.
1999: Hatem A M Hejaz; Atul Purohit; Mary F Mahon; Michael J Reed; Barry V L Potter
Synthesis and biological activity of the superestrogen (E)-17-oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: x-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5(10)-estratriene.
Journal of medicinal chemistry 1999;42(16):3188-92.
1999: M E Migaud; R L Pederick; VC Bailey; Barry V L Potter
Probing Aplysia californica adenosine 5'-diphosphate ribosyl cyclase for substrate binding requirements: design of potent inhibitors.
Biochemistry 1999;38(28):9105-14.
1999: Xiaonian Yang; M Rudolf; Mark Carew; M Yoshida; V Nerreter; Andrew M Riley; Sung-Kee Chung; Karol S Bruzik; Barry V L Potter; C Schultz; Stephen B Shears
Inositol 1,3,4-trisphosphate acts in vivo as a specific regulator of cellular signaling by inositol 3,4,5,6-tetrakisphosphate.
The Journal of biological chemistry 1999;274(27):18973-80.
1999: Stevan Rakovic; Y Cui; S Iino; Antony Galione; G A Ashamu; Barry V L Potter; Derek A Terrar
An antagonist of cADP-ribose inhibits arrhythmogenic oscillations of intracellular Ca2+ in heart cells.
The Journal of biological chemistry 1999;274(25):17820-7.
1999: Changsheng Liu; R J Davis; S R Nahorski; S Ballereau; Bernard Spiess; Barry V L Potter
Synthesis, calcium mobilizing, and physicochemical properties of D-chiro-inositol 1,3,4,6-tetrakisphosphate, a novel and potent ligand at the D-myo-inositol 1,4,5-trisphosphate receptor.
Journal of medicinal chemistry 1999;42(11):1991-8.
1999: Paola Lo Surdo; Matthew J Bottomley; Alexandre Arcaro; Gregg Siegal; George Panayotou; Andrew Sankar; Piers R J Gaffney; Andrew M Riley; Barry V L Potter; Michael D Waterfield; Paul C Driscoll
Structural and biochemical evaluation of the interaction of the phosphatidylinositol 3-kinase p85alpha Src homology 2 domains with phosphoinositides and inositol polyphosphates.
The Journal of biological chemistry 1999;274(22):15678-85.
1999: E Baraldi; Kristina Djinovic-Carugo; M Hyvönen; Paola Lo Surdo; Andrew M Riley; Barry V L Potter; R O'Brien; J E Ladbury; Matti Saraste
Structure of the PH domain from Bruton's tyrosine kinase in complex with inositol 1,3,4,5-tetrakisphosphate.
Structure (London, England : 1993) 1999;7(4):449-60.
1999: Atul Purohit; Hatem A M Hejaz; L W Lawrence Woo; A E van Strien; Barry V L Potter; Michael J Reed
Recent advances in the development of steroid sulphatase inhibitors.
The Journal of steroid biochemistry and molecular biology 1999;69(1-6):227-38.
1999: M Reyes-Harde; Ruth Empson; Barry V L Potter; Antony Galione; Patric Stanton
Evidence of a role for cyclic ADP-ribose in long-term synaptic depression in hippocampus.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(7):4061-6.
1999: Andreas H Guse; CP da Silva; I Berg; Alla Skapenko; Klaus Weber; P Heyer; Martin Hohenegger; G A Ashamu; H Schulze-Koops; Barry V L Potter; Georg W Mayr
Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose.
Nature 1999;398(6722):70-3.
1999: P H Hirst; Andrew M Riley; Stephen Joseph Mills; I D Spiers; D R Poyner; S Freeman; Barry V L Potter; A W Smith
Inositol polyphosphate-mediated iron transport in Pseudomonas aeruginosa.
Journal of applied microbiology 1999;86(3):537-43.
1999: Rachel D Marwood; Andrew M Riley; Vanessa Correa; Colin W Taylor; Barry V L Potter
Simplification of adenophostin A defines a minimal structure for potent glucopyranoside-based mimics of D-myo-inositol 1,4,5-trisphosphate.
Bioorganic & medicinal chemistry letters 1999;9(3):453-8.
1999: MD Beecroft; Jonathan Marchant; Andrew M Riley; N C Van Straten; G A Van der Marel; J H Van Boom; Barry V L Potter; Colin W Taylor
Acyclophostin: a ribose-modified analog of adenophostin A with high affinity for inositol 1,4,5-trisphosphate receptors and pH-dependent efficacy.
Molecular pharmacology 1999;55(1):109-17.
1998: CP da Silva; Barry V L Potter; Georg W Mayr; Andreas H Guse
Quantification of intracellular levels of cyclic ADP-ribose by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;707(1-2):43-50.
1998: L W Lawrence Woo; Nicola M Howarth; Atul Purohit; Hatem A M Hejaz; Michael J Reed; Barry V L Potter
Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase.
Journal of medicinal chemistry 1998;41(7):1068-83.
1998: Atul Purohit; K A Vernon; A E Hummelinck; L W Lawrence Woo; Hatem A M Hejaz; Barry V L Potter; Michael J Reed
The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity.
The Journal of steroid biochemistry and molecular biology 1998;64(5-6):269-75.
1998: Atul Purohit; Barry V L Potter; M G Parker; Michael J Reed
Steroid sulphatase: expression, isolation and inhibition for active-site identification studies.
Chemico-biological interactions 1998;109(1-3):183-93.
1997: C Liu; Barry V L Potter
Synthesis of 3-Position-Modified Analogues of myo-Inositol 1,4,5-Trisphosphate, Tools for Investigation of the Polyphosphoinositide Pathway of Cellular Signaling.
The Journal of organic chemistry 1997;62(24):8335-40.
1997: Masato Hirata; Hiroshi Takeuchi; Andrew M Riley; Stephen Joseph Mills; Y Watanabe; Barry V L Potter
Inositol 1,4,5-trisphosphate receptor subtypes differentially recognize regioisomers of D-myo-inositol 1,4,5-trisphosphate.
The Biochemical journal 1997;328 ( Pt 1)():93-8.
1997: Jonathan Marchant; MD Beecroft; Andrew M Riley; David J Jenkins; Rachel D Marwood; Colin W Taylor; Barry V L Potter
Disaccharide polyphosphates based upon adenophostin A activate hepatic D-myo-inositol 1,4,5-trisphosphate receptors.
Biochemistry 1997;36(42):12780-90.
1997: CT Murphy; Andrew M Riley; C J Lindley; David J Jenkins; John Westwick; Barry V L Potter
Structural analogues of D-myo-inositol-1,4,5-trisphosphate and adenophostin A: recognition by cerebellar and platelet inositol-1,4,5-trisphosphate receptors.
Molecular pharmacology 1997;52(4):741-8.
1997: G A Ashamu; Jaswinder Sethi; Antony Galione; Barry V L Potter
Roles for adenosine ribose hydroxyl groups in cyclic adenosine 5'-diphosphate ribose-mediated Ca2+ release.
Biochemistry 1997;36(31):9509-17.
1997: Jaswinder Sethi; Ruth Empson; VC Bailey; Barry V L Potter; Antony Galione
7-Deaza-8-bromo-cyclic ADP-ribose, the first membrane-permeant, hydrolysis-resistant cyclic ADP-ribose antagonist.
The Journal of biological chemistry 1997;272(26):16358-63.
1997: Atul Purohit; V A Froome; D Y Wang; Barry V L Potter; Michael J Reed
Measurement of oestrone sulphatase activity in white blood cells to monitor in vivo inhibition of steroid sulphatase activity by oestrone-3-O-sulphamate.
The Journal of steroid biochemistry and molecular biology 1997;62(1):45-51.
1997: Andreas H Guse; CP da Silva; Klaus Weber; C N Armah; G A Ashamu; C Schulze; Barry V L Potter; Georg W Mayr; H Hilz
1-(5-phospho-beta-D-ribosyl)2'-phosphoadenosine 5'-phosphate cyclic anhydride induced Ca2+ release in human T-cell lines.
European journal of biochemistry / FEBS 1997;245(2):411-7.
1997: Nicola M Howarth; Atul Purohit; Michael J Reed; Barry V L Potter
Estrone sulfonates as inhibitors of estrone sulfatase.
Steroids 1997;62(4):346-50.
1997: Andreas H Guse; I Berg; CP da Silva; Barry V L Potter; Georg W Mayr
Ca2+ entry induced by cyclic ADP-ribose in intact T-lymphocytes.
The Journal of biological chemistry 1997;272(13):8546-50.
1997: Andreas H Guse; CP da Silva; Barry V L Potter; Georg W Mayr
Ca(2+)-signalling in human T-lymphocytes. Potential roles for cyclic ADP-ribose and 2'-phospho-cyclic ADP-ribose.
Advances in experimental medicine and biology 1997;419():431-6.
1997: VC Bailey; Jaswinder Sethi; S M Fortt; Antony Galione; Barry V L Potter
7-Deaza cyclic adenosine 5'-diphosphate ribose: first example of a Ca(2+)-mobilizing partial agonist related to cyclic adenosine 5'-diphosphate ribose.
Chemistry & biology 1997;4(1):51-61.
1996: D J Jenkins; A M Riley; Barry V L Potter
Chiral Cyclopentane-Based Mimics of D-myo-Inositol 1,4,5-Trisphosphate from D-Glucose.
The Journal of organic chemistry 1996;61(22):7719-26.